SEATTLE , Feb. 11, 2019 /PRNewswire/ -- CTI BioPharma Corp. (NASDAQ:CTIC) today announced that it has received a $10 million milestone payment from Teva Pharmaceutical Industries Ltd. related to the achievement of sales milestones for TRISENOX ® (arsenic trioxide).
- Company announces continuation of PAC203 study following third interim review - SEATTLE , Feb. 1, 2019 /PRNewswire/ -- CTI BioPharma Corp. (NASDAQ:CTIC) today announced that the Company will withdraw its European Marketing Authorization Application (MAA) for pacritinib as a treatment for
3101 Western Ave., #800
Seattle, WA 98121
T +1 206-282-7100 T +1 800-215-2355 (US only) F +1 206-284-6206